THE LANCET ONCOLOGY COMMENT

Expert commentaries that accompany original articles published in The Lancet Oncology. Most commentaries are commissioned. Unsolicited commentaries may be peer reviewed.

Page 1 of 9

« start ‹ previous ... 1 2 3 4 5 ... next › end »

Personalised Medicine in Oncology: Questions for the Next 20 Years

J-Y Blay, D Lacombe, F Meunier, R Stupp, 2012 May 1, Lancet Oncol

Molecular characterisation of tumour cells enables refinement of classifications for many cancers and can sometimes guide treatment. Malignant diseases are no longer classified only by tumour site and...

The STAMPEDE Trial and Celecoxib: How to Adapt?

AJ Armstrong, 2012 May 1, Lancet Oncol

In The Lancet Oncology, Nicholas James and colleagues present the first results of the STAMPEDE randomised trial in advanced prostate cancer, describing interim results for patients who received androgen-deprivation...

Integration of Palliative and Supportive Cancer Care in Asia

JJ Chin, CW Ho, H Arima, et al, 2012 May 1, Lancet Oncol

Good cancer care should aim to prevent or relieve suffering caused by cancer and its treatment. This approach can have quantifiable outcomes for patients, including prolonged and improved quality of life....

Intensifying Tumour Immunity Through Combination Therapy

G Dranoff, 2012 May 1, Lancet Oncol

Combination regimens of cytotoxic chemotherapeutic drugs are a mainstay of cancer treatment. Historically, the integration of several agents with distinct mechanisms of action and non-overlapping toxic...

Revolutionising Cancer Care in South Africa

L Gouws, D Eedes, E Marais, et al, 2012 May 1, Lancet Oncol

South Africa is embarking on major changes to its existing two-tier health-care structure. This dual system consists of a private health-care system, comparable with some of the best systems in developed...

A New Generation of EGFR Tyrosine-Kinase Inhibitors in NSCLC

FR Hirsch, PA Bunn, 2012 May 1, Lancet Oncol

The results of two clinical trials that assessed the activity of afatinib, a novel irreversible ErbB-family blocker, are presented in The Lancet Oncology. One of these studies, LUX-Lung 1, randomly allocated...

Is Benefit of Maintenance Therapy for NSCLC Best Defined by Progression-Free Survival?

K Reckamp, 2012 May 1, Lancet Oncol

Maintenance therapy for non-small-cell lung cancer (NSCLC) has gained acceptance in selected patients after the approval of pemetrexed and erlotinib for such use by the US Food and Drug Administration...

Screening for Anal Cancer: Endpoints Needed

N Wentzensen, 2012 May 1, Lancet Oncol

Anal cancer is very rare in the general population, but much more common in well defined, high-risk populations, including women with a previous cervical precancer, men who have sex with men (MSM), and...

Long-Term Outcome of Breast Conserving Therapy

JR Benson, 2012 Apr 1, Lancet Oncol

In The Lancet Oncology, Saskia Litière and colleagues present results of the long-term follow-up of a seminal phase 3 trial comparing breast conserving therapy (BCT) and modified radical mastectomy (MRM)...

Inflammatory HER2-Positive Breast Cancer

LY Dirix, PB Vermeulen, 2012 Apr 1, Lancet Oncol

Although inflammatory breast cancer is a rare form of locally advanced breast cancer (making up 1—5% of cases), it remains a substantial and vexing clinical issue. Such cancer is characterised by rapid...